V Consensus Meeting of the Spanish Society for Liver Transplant on high-risk recipients, immunosupression scenarios and management of hepatocarcinoma on the transplant waiting list;V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

Cirugia Espanola

Volumn 93, Issue 10, 2015, Pages 619-637

  Pardo, Fernando ^a   Pons, José Antonio ^b   Briceño, Javier ^c   Delgado, Javier Briceño ^c   Bilbao, Itxarone ^d   Bru, Rubén Ciria ^c   Aguilar, José Luis Fernández ^e,m   Salcedo, Magdalena ^f   Turrión, Víctor Sánchez ^g   Serrano, Trinidad ^h   de la Mata, Manuel ^c   Abradelo, Manuel ⁱ   Pérez, Isolina Baños ^g   Barrera, Asterio ^j   Barrera, Manuel ^k   Calatayud, David ^l   d'Avola, Delia ^a   Galeano, Francisco ⁿ   Gil, Francisco Agustín García ^h   Garrote, Daniel ^o   Gastaca, Mikel ^p   Gutiérrez, Manuel Gómez ^q   Santamaría, Manuel López ^r   Vázquez Daga, Javier Nuño ^s   Robles, Ricardo ^b   Laiz, Gonzalo Rodríguez ^t   Sanjuan, Juan Carlos Rodríguez ^u   Rubín, Angel ^v   Sousa, José Manuel ^w   Tomé, Santiago ^x   Javier Xiol, F ^y   Herrero, José Ignacio ^a   Varo, Evaristo ^x   Aguilera, Victoria ^v   álamo, José María ^w   Bellot, Pablo ^t   Castells, Lluís ^d   Crespo, Gonzalo ^y   Cuervas Mons, Valentín ^g   Fábrega, Emilio ^u   Diéguez, Luisa González ^z   Graus, Javier ^s   Jara, Paloma ^r   Jiménez, Carlos ⁱ   Jiménez, Miguel ^a   Lladó, Laura ^y   Molina, Esther ^x   Narvaez, Isidoro ⁿ   de Urbina, Jorge Ortiz ^p   Otón, Elena ^k   Antolín, Gloria Sánchez ^j   Prieto, Martín ^v   Ramos, Emilio ^y   Bañares, Rafael ^f   Bárcena, Rafael ^s   Blanco, Gerardo ⁿ   Bustamante, Francisco Javier ^p   Casafont, Fernando ^u   Charco, Ramon ^d   Delgado, Manuel ^q   Castroagudín, Javier Fernández ^x   Ferrer, Teresa ^w   Fundora, Yiliam ^o   Fuster, Josep ^l   Bernardo, Carmen García ^z   Pajares, Félix García ^j   Andújar, Rafael López ^v   Pérez, Sara Lorente ^h   Montero, José Luis ^c   Pascual, Sonia ^t   Ramírez, Pablo ^b   Rodrigo, Juan Miguel ^m   Bosque, María Arántzazu Varona ^k   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Hospital Regional Universitario   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^k HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^l Hospital Universitario Clínic   (Spain)

^m HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁿ HOSPITAL INFANTA CRISTINA   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p HOSPITAL DE CRUCES   (Spain)

^q HOSPITAL JUAN CANALEJO   (Spain)

^r HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^s HOSPITAL RAMÓN Y CAJAL   (Spain)

^t HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^u HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^v HOSPITAL UNIVERSITARIO LA FE   (Spain)

^w HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^x University Hospital of Santiago de Compostela   (Spain)

^y HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^z HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

Hepatocarcinoma; High risk receptor; Immunosuppression; Liver transplant

Indexed keywords

CONSENSUS; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; CONSENSUS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; WAITING LISTS;

EID: 84949318121     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/j.ciresp.2015.04.007     Document Type: Article

References (150)

1. Registro Español de Trasplante Hepático [consultado 8 Oct 2014]. Disponible en: http://www.sethepatico.org.
2. James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 1999, 354:1636-1639.
3. Neuberger J., Gimson A., Davies M., Akyol M., O'Grady J., Burroughs A., et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008, 57:252-257. for Liver Advisory Group of UK Blood and Transplant.
4. Nachmany I., Dvorchik I., de Vera M., Fontes P., Demetris A., Humar A., et al. A validated model for predicting outcome after liver transplantation: Implications on transplanting the extremely sick. Transplant Int 2013, 26:1108-1115.
5. Martin P., Dimartini A., Feng S., Brown R., Fallon M. Evaluation for liver transplantation in adults: 2013 Practice guideline by the American Association or the study of Liver Diseases and the American Society of Transplantation. Hepatology 2014, 59:1144-1165.
6. Disponible en: http://www.ont.es/infesp/Paginas/DatosdeDonacionyTrasplante.aspx [consultado 8 Oct 2014].
7. Knight M., Barber K., Gimson A., Collett D., Neuberger J. Implications of changing the minimal survival benefit in liver transplantation. Liver Transpl. 2012, 18:549-557.
8. Keller E.J., Kwo P.Y., Helft P.R. Ethical considerations surrounding survival benefit-based liver allocation. Liver Transpl 2014, 20:140-146.
9. Cuervas-Mons V. Receptores de trasplante hepático de alto riesgo. Gastroenterol Hepatol 2006, 29:65-69.
10. Briceño J., Ciria R., de la Mata M. Donor-recipient matching: Myths and realities. J Hepatol 2013, 58:811-820.
11. Merion R.M. When is a patient too well and when is a patient too sick for a liver transplant?. Liver Transpl. 2004, 10(Suppl 2):S69-S73.
12. Freeman R.B., Wiesner R. Should we change the priority for liver allocation for patients with the highest MELD score?. Hepatology 2012, 55:14-15.
13. Sharma P., Schaubel D.E., Gong Q., Guidinger M., Merion R.M. End-stage liver disease candidates at the highest MELD scores have higher waitlist mortality than status-1 A candidates. Hepatology 2012, 55:192-198.
14. Abouljoud M.S., Brown K.A., Nerenz D.R. Sicker patients with end-stage liver disease cost more: A quick fix. An editorial on assessing variation in the costs of care among patients awaiting liver transplantation. Am J Transpl 2014, 14:9-10.
15. Axelrod D.A., Dzebisashvili N., Lentine K., Segev D.L., Dickson R., Tuttle-Newhall E., et al. Assessing variation in the costs of care among patients awaiting liver transplantation. Am J Transplant 2014, 14:70-78.
16. Bruns H., Lozanovski V.J., Schultze D., Hillebrand N., Hinz U., Büchler M.W., et al. Peter Schemmer prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: A multivariate analysis. Plos One 2014, 9:e98782.
17. Kristin K.B., Stafinski T.D., Menon D. Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. Plos One 2013, 8:e80661.
18. De la Mata M., Cuende N., Huet J., Bernardos A., Ferrón J.A., Santoyo J., et al. Model for end-stage liver disease score-based allocation of donors for liver transplantation: A Spanish multicenter experience. Transplantation. 2006, 82:1429-1435.
19. Northup P.G., Intagliata N.M., Shah N.L., Pelletier S.J., Berg C.L., Argo C.K. Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for end-stage liver disease (MELD) inflation. Hepatology 2015, 61:285-291.
20. Schaubel D.E., Sima C.S., Goodrich N.P., Feng S., Merion R.M. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008, 8:419-425.
21. Schaubel D.E., Guidinger M.K., Biggins S.W., Kalbfleisch J.D., Pomfret E.A., Sharma P., et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009, 9(pt 2):970-981.
22. Rana A., Hardy M.A., Halazum K.J., Woodland D.C., Ratner L.E., Samstein B., et al. Survival outcomes following liver transplantation (SOFT) score: A novel method to predict patient survival following liver transplantation. Am J Transplant 2008, 8:2537.
23. Rana A., Jie T., Porubsky M., Habib S., Rilo H., Kaplan B., et al. The survival outcomes following liver transplantation (SOFT) score: Validation with contemporaneous data and stratification of high-risk cohorts. Clin Transplant 2013, 27:627-632.
24. Desai N.M., Mange K.C., Crawford M.D., Abt P.L., Frank A.M., Markmann J.W., et al. Predicting outcome after liver transplantation: Utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation. 2004, 77:99-106.
25. Burroughs A.K., Sabin C.A., Rolles K., Delvart V., Karam V., Buckels J., et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: Predictive models for outcome. Lancet. 2006, 367:225-232.
26. Briceño J., Cruz-Ramírez M., Prieto M., Navasa M., Ortiz de Urbina J., Orti R., et al. Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. J Hepatol. 2014, 61:1020-1028.
27. Rodriguez-Castro K.I., Porte R.J., Nadal E., Germani G., Burra P., Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation 2012, 94:1145-1153.
28. Ponziani F.R., Zocco M.A., Senzolo M., Pompili M., Gasbarrini A., Avolio A.W. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. Transplant Rev 2014, 28:92-101.
29. Francoz C., Valla D., Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012, 57:203-212.
30. Huard G., Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: A systematic review. International Journal of Hepatology 2012, 8:672986.
31. Francoz C., Belghiti J., Vilgarin V., Sommacale D., Paradis V., Condat B., et al. Splanchnic vein trombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005, 54:691.
32. Nonami T., Yokoyama I., Iwatsuki S., Starzl T.E. The incidente of portal vein trombosis at liver transplantation. Hepatology 1992, 16:1195.
33. Stieber A.C., Zetti G., Todo S., Tzakis A.G., Fung J.J., Marino I., et al. The spectrum of portal vein thrombosis in liver transplantation. Ann Surg 1991, 213:199.
34. Gayowski T.J., Marino I.R., Doyle H.R., Echeverri L., Mieles L., Todo S., et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996, 60:333.
35. Yerdel M.A., Gunson B., Mirza D., Karayalçin K., Olliff S., Buckels J., et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000, 69:1873.
36. Jamieson N.V. Changing perspectives in portal vein thrombosis and liver transplantation. Transplantation 2000, 69:1772.
37. Charco R., Fuster J., Fondevila C., Ferrer J., Mans E., García-Valdecasas J.C. Portal vein thrombosis in liver transplantation. Transplant Proc 2005, 37:3904.
38. Bauer J., Johnson S., Durham J., Ludkowski M., Trotter J., Bak T., et al. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl 2006, 12:1544.
39. Amitrano L., Brancaccio V., Guardascione M.A., Margaglione M., Iannaccone L., D'Andrea G., et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000, 31:345.
40. Amitrano L., Guardascione M.A., Brancaccio V., Margaglione M., Manguso F., Iannaccone L., et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004, 40:736.
41. Davidson B.R., Gibson M., Dick R., Burroughs A., Rolles K. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation 1994, 57:1174.
42. Egawa H., Tanaka K., Kasahara M., Takada Y., Oike F., Ogawa K., et al. Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl 2006, 12:1512.
43. Dumortier J., Czyglik O., Poncet G., Blanchet M.C., Boucaud C., Henry L., et al. Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transpl 2002, 2:934.
44. Senzolo M., Sartori T., Rossetto V. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012, 32:919-927.
45. Francoz C., Belghiti J., Vilgrain V., Sommacale D., Paradis V., Condat B., et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005, 54:691-697.
46. Amitrano L., Guardascione M.A., Menchise A., Martino R., Scaglione M., Giovine S., et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010, 44:448-451.
47. Zecchini R., Ferrari A., Bernabucci V., Lei B., Vukotic R., de Maria N., et al. Anticoagulant therapy is safe and effective in preventing portal vein thrombosis (PVT) in advanced cirrhotic patients: A prospective randomized controlled study. J Hepatol 2010, 52:S459.
48. Han G., Qi X., He C., Yin Z., Wang J., Xia J., et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011, 54:78-88.
49. Luca A., Miraglia R., Caruso S., Milazzo M., Sapere C., Maruzzelli L., et al. Short and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011, 60:846-852.
50. Senzolo M., Tibbals J., Cholongitas E., Triantos C.K., Burroughs A.K., Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006, 23:767-775.
51. Robles R., Fernandez J.A., Hernández Q., Marín C., Ramírez P., Sánchez-Bueno F., et al. Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation. Clin Transplant. 2004, 18:79-84.
52. Nikitin D., Jennings L.W., Khan T., Vasani S., Ruiz R., Sanchez E.Q., et al. Twenty years' follow-up of portal vein conduits in liver transplantation. Liver Transpl 2009, 15:400.
53. Hibi T., Nishida S., Levi D., Selvaggi G., Tekin A., Fan J., et al. When and why portal vein thrombosis maters in liver transplantation. A critical audit of 174 cases. Ann Surg 2014, 259:760-766.
54. Bangui P., Lim C., Salloum C., Andreani P., Sebbagh M., Hoti E., et al. Caval inflow to the graft for liver transplantation in patients with diffuse portal vein thrombosis. A 12-year experience. Ann Surg 2011, 254:1008-1016.
55. Englesbe M.J., Schaubel D.E., Cai S., Guidinger M.K., Merion R.M. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010, 16:999-1005.
56. Wu T.-H., Lin Y.-S., Lee C-F., Wu T.-J., Yu M.-C., Chan K.-M. Clinical analysis and strategy for liver transplantation in patients with pre-existing portal vein thrombosis. Chang Gung Medi J 2011, 34:426-433.
57. Moon D.B., Lee S.G., Ahn C.S., Hwang S., Kim K.H., Ha T.Y., et al. Management of extensive nontumorous portal vein trombosis in adult living donor liver transplantation. Transplantation 2014, 97:S23-S29.
58. World Health Organization [consultado 8 Oct 2014]. Disponible en: www.who.int/mediacentre/factsheets/fs311/en.
59. Bilbao I, Guevara A, Dopazo D, Castells L, Lázaro JL, Sapisochin G, Campos I, Charco R. Abastract y Comunicación oral. Obesidad y síndrome metabólico tras el trasplante hepático a lo largo de 15 años [consultado 8 Oct 2014]. Disponible en: https://www.setrasplante.org/SET Madrid 2012.
60. Bilbao I, Castells L, Dopazo C, Lázaro J, Caralt M, de la Serna S, Moreira C, Charco R. Abstract y comunicación oral n.o 26. Impacto del índice de masa corporal en la supervivencia a largo plazo de los pacientes trasplantados hepáticos [consultado 8 Oct 2014]. Disponible en: https://www.setrasplante.org/SET.
61. Orci L., Majno P.E., Berney T., Morel P., Mentha G., Toso C. The impact of wait list body mass index changes on the outcome alter liver transplantation. Transpl Int 2013, 26:170-176.
62. Saab S., Lalezari D., Pruthi P., Alper T., Tong M.J. The impact of obesity on patient survival in liver transplant recipients: A meta-analysis. Liver Int 2015, 35:164-170.
63. Montejo González J.C., Calvo Hernández M.V. Trasplante hepático. Implicaciones nutricionales. Nutr Hosp 2008, 23(Supl. 2):34-40.
64. Le Cornu K.A., McKiernan F.J., Kapadia S.A., Neuberger J.M. A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. Transplantation 2000, 69:1364-1369.
65. Tanaka T., Renner E.L., Seitzner N., Therapondos G., Lilly L.B. The impact of obesity as determined by modified body mass index on long-term outcome after liver transplantation: Canadian single-center experience. Transplant Proc 2013, 45:2288-2294.
66. Global Database on Body Mass Index - World Health Organization [consultado 8 Oct 2014]. Disponible en: www.who.int/bmi/index.jsp?introPage=intro_3.html.
67. Lin M.Y., Tavakol M.M., Sarin A., Amirkiai S.M., Rogers S.J., Carter J.T., et al. Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates. Surg Obes Relat Dis 2013, 9:653-658.
68. Choudhary N.S., Saigal S., Saraf N., Puri R., Soin A. Innovative approach using an intragastric balloon for weight loss in a morbidly obese patient undergoing liver transplantation. Liver Transpl 2013, 19:235.
69. Weingarten T.N., Mantilla C.B., Swain J.M., Kendrick M.L., Oberhansley J.M., Burcham R.J., et al. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg 2011, 21:1714-1720.
70. Mosko J.D., Nguyen G.C. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9:897-901.
71. Heimbacha J.K., Watt K.D.S., Poterucha J.J., Francisco Ziller N., Cecco S.D., Charlton M.R., et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation 2013, 13:363-368.
72. Butte J., Devaud N., Jarufe N.P., Boza C., Pérez G., Torres J., et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. Obes Surg 2007, 17:1517-1519.
73. Al-Nowaylati A.R., al-Haddad J.S., Dorman R.B., Alsaied O.A., Lake J.R., Chinakotta S., et al. Gastric bypass after liver transplantation. Liver Transpl 2013, 19:1324-1329.
74. Anastasio L.R., de Angelis Pereira M.C., Vilela E.G., Lima A.S., Correira M.I. Overweight in liver transplant recipients. Rev Col Bras Cir 2013, 40.. 502-506.
75. Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl 2009, 15:S83-S89.
76. Kouz J., Vincent C., Leong A., Dorais M., Rakel A. Weight gain after orthotopic liver transplantation: Is NAFLD cirrhosis a risk factor for greater weight gain?. Liver Transpl 2014, 20:1266-1274.
77. Anastácio L.R., Ferreira L.G., Liboredo J.C., Ribeiro H.S., Lima A.S., Vilela E.G., et al. Overweight, obesity and weight gain un to three years after liver transplantation. Nutr Hosp 2012, 27:1351-1356.
78. Hakeem A.R., Cockbain A.J., Raza S.S., Pollard S.G., Toogood G.J., Attia M.A., et al. Increased morbidity in overweight and obese liver transplant recipients: A single-center experience of 1325 patients from the United Kingdom. Liver Transpl 2013, 19:551-562.
79. Perez-Proto S.E., Quintini C., Reynolds L.F., You J., Cywinski J.B., Sessler D.I., et al. Comparable graft and patient survival in lean and obese liver transplant recipients. Liver Transpl 2013, 19:907-915.
80. Shinghal A., Wilson G.C., Wima K., Quillin R.C., Cuffy M., Anwar N., et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 2015, 28:148-155.
81. Foster M.T., Pagliassotti M.J. Metabolic alterations following visceral fat removal and expansion: Beyond anatomic location. Adipocyte 2012, 1:192-199.
82. Dare A.J., Plank L.D., Phillips A.R., Gane E.J., Harrison B., Orr D., et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl 2014, 20:281-290.
83. Manoushagian S., Meshkov A. Evaluation of solid organ transplant candidates for coronary artery disease. Am J Transpl 2014, 4:2228-2234.
84. Dare A.J., Plank L.D., Phillips A.R., Gane E.J., Harrison B., Orr D., et al. Additive effect of pretransplant obesity, diabetes and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl 2014, 20:281-290.
85. Gologorsky E., Pretto E.A., Fukazawa K. Coronary artery disease and its risk factors in patients presenting for liver transplantation. J Clin Anesth. 2013, 25:618-623.
86. Carey W.D., Dumot J.A., Pimentel R.R., Barnes D.S., Hobbs R.E., Henderson J.M., et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995, 59:859-864.
87. Hardwaj A.A., Heuman D.M., Jovin I.S. Coronary events in patients undergoing orthotopic liver transplantation: Perioperative evaluation and management. Clin Transpl 2013, 27:E207-E215.
88. Lentine K.L., Costa S.P., Weir M.R., Robb J.F., Fleisher L.A., Kasiske B.L., et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2012, 61:7-66.
89. Cassagneau P., Jacquier A., Giorgi R., Amabile N., Gaubert J.Y., Cohen F., et al. Prognostic value of preoperative coronary computed tomography in patients treated by orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2012, 24:558-562.
90. Ehtisham J., Altieri M., Salame E., Saloux E., Ollivier I., Hamon M. Coronary artery disease in orthotopic liver transplantation: Pretransplant assessment and management. Liver Transpl 2010, 16:550-557.
91. Nicolau-Raducu R., Gitman M., Ganier D., Loss G.E., Cohen A.J., Patel H., et al. Adverse cardiac events after orthotopic liver transplantation: A cross-sectional study in 389 consecutive patients. Liver Transpl 2015, 21:13-21.
92. Herrero J.I. De novo malignancies following liver transplantation: Impact and recommendations. Liver Transpl 2009, 15(Suppl 2):S90-S94.
93. Watt K.D.S., Pedersen R.A., Kremers W.K., Heimbach J.K., Charlton M.R. Evolution of causes and risk factors for mortality post-liver transplant: Results of the NIDDK long-term follow-up study. Am J Transplant. 2010, 10:1420-1427.
94. Rubin A., Sánchez-Montes C., Aguilera V., Juan F.S., Ferrer I., Moya A., et al. Long-term outcome of long-term liver transplant survivors. Transplant Int. 2013, 26:740-750.
95. Herrero J.I., Pardo F., Davola D., Alegre F., Rotellar F., Inarrairaegui M., et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. Liver Transpl. 2011, 17:402-408.
96. Wimmer C.D., Angele M.K., Schwarz B., Pratschke S., Rentsch M., Khandoga A., et al. Impact of cyclosporine versus tacrolimus on the incidence of de novomalignancy following liver transplantation: A single center experience with 609 patients. Transplant Int 2013, 26:999-1006.
97. Sampaio M.S., Cho Y.W., Qazi Y., Bunnapradist S., Hutchinson I.V., Shah T. Posttransplant malignancies in solid organ adult recipients. Transplantation 2012, 94:990-998.
98. Tjon A.S.W., Nicolaas J.S., Kwekkeboom J., de Man R.A., Kazemier G., Tilanus H.W., et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age. Liver Transpl. 2010, 16:837-846.
99. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Heroux A.L., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990, 323:1723-1728.
100. Abdelmalek M.F., Humar A., Stickel F., Andreone P., Pascher A., Barroso E., et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant. 2012, 12:694-705.
101. Knoll G.A., Kokolo M.B., Mallick R., Beck A., Buenaventura C.D., Ducharme R., et al. Effect of sirolimus on malignancy and survival after kidney transplantation: Systematic review and meta-analysis of individual patient data. BMJ. 2014, 349:g6679-g6689.
102. Euvrard S., kanitakis J. Skin cancers after liver transplantation: What to do?. J Hepatol. 2006, 44:27-32.
103. Benlloch S., Berenguer M., Prieto M., Moreno R., Juan F.S., Rayon M., et al. De novo internal neoplasms after liver transplantation: Increased risk and aggressive behavior in recent years?. Am J Transplant. 2004, 4:596-604.
104. Stallone G., Schena A., Infante B., di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005, 352:1317-1323.
105. Reshef R., Vardhanabhuti S., Luskin M.R., Heitjan D.F., Hadjiliadis D., Goral S., et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011, 11:336-347.
106. Euvrard S., Morelon E., Rostaing L., Goffin E., Brocard A., Tromme I., et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012, 367:329-339.
107. Gomez-Camarero J., Salcedo M., Rincon D., Iacono O.L., Ripoll C., Hernando A., et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007, 84:786-791.
108. Berenguer M., Charco R., Manuel Pascasio J., Ignacio Herrero J. Spanish Society of Liver Transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. Liver Int Internet. 2012, 32:712-731. on behalf of the Sociedad Española de Trasplante Hepático.
109. Samonakis D.N., Germani G., Burroughs A.K. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 56 2012, 973-983.
110. Kwo P.Y., Mantry P.S., Coakley E., Te H.S., Vargas H.E., Brown R., et al. An Interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014, 371:2375-2382.
111. Veldt B.J., Poterucha J.J., Watt K.D.S., Wiesner R.H., Hay J.E., Kremers W.K., et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008, 8:2426-2433.
112. Rodríguez-Perálvarez M., de la Mata M., Burroughs A.K. Liver transplantation. Curr Opin Organ Transplant. 2014, 19:253-260.
113. lvarez M.R.G-P., Germani G., Papastergiou V., Tsochatzis E., Thalassinos E., Luong T.V., et al. Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013, 58:262-270.
114. Cholongitas E., Mamou C., Rodríguez-Castro K.I., Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review. Transplant Int. 2014, 27:1039-1049.
115. Klintmalm G.B., Nashan B. The role of mTOR Inhibitors in liver transplantation: Reviewing the evidence. Journal of Transplantation 2014, 2014:1-45.
116. Clavien P.A., Lesurtel M., Bossyut P.M.M., Gores G.J., Langer B., Perrier A., et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncology 2011, 13:e11-e22.
117. Gomez-Martin C., Bustamante J., Castroagudin J.F., Salcedo M., Garralda E., Testillano M., et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2011, 18:45-52.
118. Stallone G., Infante B., Pontrelli P., Gigante M., Montemurno E., Loverre A., et al. Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011, 91:997-1004.
119. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003, 349:931-940.
120. Herrero J.I., Quiroga J., Sangro B., Girala M., Gómez-Manero N., Pardo F., et al. Conversion of liver transplant recipients on cysclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999, 5:414.
121. Ponton C., Vizcaíno L., Tomé S., Otero E., Molina E., Castroagudin J.F., et al. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction. Transplant Proc 2010, 42:656-659.
122. Planas J.M.M., Martinez V.C-M., Gonzalez E.R., Cruz A.G., Lopez-Monclus J., Sanchez-Turrion V., et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant. 2004, 4:1650-1655.
123. De Simone P., Nevens F., de Carlis L., Metselaar H.J., Beckebaum S., Saliba F., et al. Everolimus with reduced tacrolimus improves renal function in de novoliver transplant recipients: A randomized controlled trial. Am J Transplant. 2012, 12:3008-3020.
124. Vitale A., Volk M.L., de Feo T.M., Burra P., Frigo A.C., Ramirez Morales R., et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014, 60:290-297.
125. Mehta N., Dodge J.L., Goel A., Roberts J.P., Hirose R., Yao F.Y. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transplant 2013, 19:1343-1353.
126. Clavien P.A., Lesurtel M., Bossuyt P.M., Gores G.J., Langer B., Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncol. 2012, 13:e11-e22.
127. Ramos E., Ortiz de Urbina J., Santoyo J., Varo E. Grado de homogeneidad de los grupos españoles de trasplante hepático en el tratamiento del hepatocarcinoma. Med Clin (Barc) 2013, 141:406-410.
128. Toso C., Dupuis-Lozeron E., Majno P., Berney T., Kneteman N.M., Perneger T., et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012, 56:150-156.
129. Toso C., Majno P., Berney T., Morel P., Mentha G., Combescure C. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int. 2014, 27:686-695.
130. Halazun K.J., Patzer R.E., Rana A.A., Verna E.C., Griesemer A.D., Parsons R.F., et al. Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014, 60.:1957-1962.
131. Schlansky B., Chen Y., Scott D.L., Austin D., Naugler W.E. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014, 20:1045-1056.
132. Samoylova M.L., Dodge J.L., Yao F.Y., Roberts J.P. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014 Aug, 20:937-944.
133. Bitterman T., Hoteit M.A., Abt P.L., Forde K.A., Goldberg D. Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: A novel study using national data. Am J Transplant 2014, 14:1657-1663.
134. Galuppo R., McCall A., Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol 2013, 1-8.
135. Majno P., Lencioni R., Mornex F., Girard N., Poon R.T., Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary?. Liver Transpl 2011, 17. S98-108.
136. Cescon M., Cucchetti A., Ravaioli M., Pinna A.D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013, 58:609-618.
137. Martin A.P., Goldstein R.M., Dempster J., Netto G.J., Katabi N., Derrick H.C., et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation-a clinical and histological examination. Clin Transpl 2006, 20:695-705.
138. Pompili M., Mirante V.G., Rondinara G., Fassati L.R., Piscaglia F., Agnes S., et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005, 11:1117-1126.
139. DuBay D.A., Sandroussi Ch, Kachura J.R., Sing H.C., Beecroft J.R., Vollmer C.M., et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) 2011, 13:24-32.
140. Roberts J.P., Venook A., Kerlan R., Francis Y.A.O. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl 2010, 16:925-929.
141. Vitale A., Volk M.L., Pastorelli D., Lonardi S., Farinati F., Burra P., et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010, 51:165-173.
142. Truesdale A.E., Caldwell S.H., Shah N.L., Argo C.K., Al-Osaimi A.M.S., Schmitt T.M., et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011, 4:991-998.
143. Kneteman N., Livraghi T., Madoff D., de Santibañez E., Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl 2011, 17:S117-S127.
144. Duvoux C., Roudot-Thoraval F., Decaens T., Pessione F., Badran H., Piardi T., et al. Liver transplantation for hepatocellular carcinoma: A model including alfa-fetoprotein improves the performance of Milan Criteria. Gastroenterology 2012, 143:986-994.
145. Hameed B., Mehta N., Sapisochin G., Roberts J.P., Yao F.Y. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan Criteria. Liver Transpl 2014, 20:945-951.
146. Merani S., Majno P., Knetemann N.M., Berney T., Morel P., Mentha G., et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011, 55:814-819.
147. Cherqui D., Laurent A., Mocellin N., Tayar C., Luciani A., van Nhieu J.T., et al. Liver resection for transplantable hepatocellular carcinoma: Long-term survival and role of secondary liver transplantation. Ann Surg 2009, 250:738-746.
148. Llovet J.M., Mas X., Aponte J.J., Fuster J., Navasa M., Christensen E., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002, 50:123-128.
149. Sala M., Fuster J., Llovet J.M., Navasa M., Solé M., Varela M., et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004, 10:1294-1300.
150. Scatton O., Zalinski S., Terris B., Lefevre J.H., Casali A., Massault P.P., et al. Hepatocellular carcinoma developed on compensated cirrhosis: Resection as a selection tool for liver transplantation. Liver Transpl 2008, 14:779-788.